GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
RSS SUMMARY · AGGREGATED FROM TWSJ
The acquisition is set to give GSK ownership of three drug candidates for lung cancer, two of which are under FDA review for approval this year.
The acquisition is set to give GSK ownership of three drug candidates for lung cancer, two of which are under FDA review for approval this year.
The acquisition is set to give GSK ownership of three drug candidates for lung cancer, two of which are under FDA review for approval this year.
Continue Reading
The full story continues on The Wall Street Journal.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.
The Source
TWSJ
Business
Bank Indonesia Surprises With Rate Hike to Stem Rupiah Bleeding
TWSJ·3h ago·3 min read
World News
Dollar Falls After Iran, Israel Halt Strikes
TWSJ·2h ago·3 min read
World News
German Industrial Output Rises For First Time Since November Despite War
TWSJ·2h ago·3 min read
Business
China’s Exports Gain Momentum; Import Growth Picks Up
TWSJ·6h ago·3 min read
Related
On this beat
Business
Nvidia CEO sends strong message to stock market investors
THE STREET·1h ago·3 min read
Business
Airbus plans German-led alliance to replace doomed fighter jet
FT·1h ago·3 min read
Business
The heartbreaking naivete of Scott Pelley
BI·1h ago·3 min read
Business
AstraZeneca advances weight-loss pill to take aim at obesity leaders
FT·13h ago·3 min read